Jaguar Animal Health Grants U.S. Rights to Crofelemer Drugs

Jaguar Animal Health ( (JAGX) ) has shared an update.

On January 12, 2026, Jaguar Health’s subsidiary Napo Pharmaceuticals entered into a U.S. licensing and supply arrangement with Woodward Specialty, an affiliate of Future Pak, under which Future Pak becomes the exclusive U.S. marketer of Jaguar’s crofelemer-based drugs Mytesi and Canalevia-CA1, while Jaguar retains responsibility for manufacturing and supplying the products. The deal provides Jaguar with an $18 million upfront payment and up to $20 million in additional milestone and future payments, backed by limited guarantees from Future Pak, and gives Napo a time-limited option to reacquire U.S. rights to the products if additional crofelemer indications in the same formulation secure U.S. regulatory approval after a specified period; collectively, the structure delivers meaningful non-dilutive capital, simplifies Jaguar’s commercial operations in HIV supportive care and veterinary GI markets, and allows the company to sharpen its strategic focus on advancing crofelemer for rare intestinal failure indications while leveraging Future Pak’s established HIV-focused commercial infrastructure.

The most recent analyst rating on (JAGX) stock is a Hold with a $0.73 price target. To see the full list of analyst forecasts on Jaguar Animal Health stock, see the JAGX Stock Forecast page.

Spark’s Take on JAGX Stock

According to Spark, TipRanks’ AI Analyst, JAGX is a Neutral.

The score is driven primarily by weak financial performance (large ongoing losses, high leverage, and significant cash burn) and bearish technicals (price below key moving averages with negative momentum). Corporate events provide some upside from encouraging trial/FDA developments, but dilution risk and a non-meaningful negative P/E keep the overall score low.

To see Spark’s full report on JAGX stock, click here.

More about Jaguar Animal Health

Jaguar Health is a commercial-stage pharmaceutical company focused on developing and commercializing proprietary, plant-based gastrointestinal medicines for humans and animals, primarily targeting overactive bowel conditions such as chronic diarrhea. Through its subsidiaries Napo Pharmaceuticals and Napo Therapeutics, the company markets FDA-approved crofelemer-based therapies like Mytesi for noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy, and Canalevia-CA1 for chemotherapy-induced diarrhea in dogs, while also advancing rare-disease indications such as intestinal failure in markets including the U.S. and Europe.

Average Trading Volume: 727,356

Technical Sentiment Signal: Sell

Current Market Cap: $2.86M

See more insights into JAGX stock on TipRanks’ Stock Analysis page.